AstraZeneca seeks to move past China probe with Beijing R&D hub
HONG KONG, LONDON] Ever since AstraZeneca shocked investors in October with news its China chief was under investigation, the British pharmaceutical giant has tried to maintain a business-as-usual stance in its second-biggest market.
The PMCPA has dug into the industry’s LinkedIn activities once again. | The PMCPA has dug into the industry’s LinkedIn activities once again. AstraZeneca received the harshest censure in the latest ...
The investments come amid an ongoing investment fraud probe into AstraZeneca’s former China head Leon Wang—and despite ...
AstraZeneca is making a $1bn investment for the long term, but what lies in store for investors over the next 12 months? Here ...
Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, ...
AstraZeneca makes a deal to buy another biotech company, this one with a price tag that could reach $1 billion.
Cambridge: Harbour BioMed, a global biopharmaceutical company has announced a global strategic collaboration with AstraZeneca ...
LONDON (dpa-AFX) - AstraZeneca Plc. (AZN.L, AZN) announced that new study results presented at the European Lung Cancer Congress (ELCC) 2025, demonstrated the role of the company's TAGRISSO ...
The AstraZeneca PLC ADR AZN slipped 1.12% to $74.09 Monday, on what proved to be an all-around positive trading session for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback